Is my prescription tied to vascepa alerts?

Vascepa Patent Exclusivity and Prescription

[1] Vascepa, a prescription medication used to lower triglycerides in patients with very high levels, is owned by Amarin Pharmaceuticals. The company holds a patent for the active ingredient, icosapent ethyl, until 2029 in the United States.

What this means for prescriptions:

In 2022, the Court of Appeals for the Federal Circuit overturned a US FDA approved label change, and as of now the only FDA approved label change is still being debated, but in December 2024, Amarin Pharmaceutical is still allowed to continue selling the drug with previous label, however the FDA has agreed to a partial label to include the FDA approval for cardiovascular event risk reduction. This allows patients to continue taking Vascepa, but manufacturers of generic versions, like those from Alembic Pharmaceuticals [2], and other generic competitors, may still challenge the exclusivity rights held by Amarin Pharmaceuticals, as they did previously in the courts.

When does exclusivity expire?

Amarin Pharmaceuticals' patent for icosapent ethyl is set to expire in 2029; however, any potential exclusivity agreements, like those offered through a Risk Evaluation and Mitigation Strategy (REMS), are separate from the patent and will have their own end dates [3]. This may allow earlier release of generic versions of the drug. Generic competition can lead to reduced prices for patients, but the process of generic drug approval is lengthy and regulated by the FDA.

How to stay informed about Vascepa prescriptions:

If you are taking Vascepa, it is essential to stay in close contact with your healthcare provider to discuss any updates to your treatment plan or changes to the availability of the medication.

Sources:
[1] DrugPatentWatch.com. Amarin Pharmaceuticals icosapent ethyl patent information.
[2] Alembic Pharmaceuticals - Vascepa Generic Challenge.
[3] FDA - Risk Evaluation and Mitigation Strategies.